In Brief: Aspirin professional labeling
This article was originally published in The Tan Sheet
Executive Summary
Aspirin professional labeling: Aspirin Foundation of America, in a recent letter to FDA, expresses support for the agency's June 13 proposal to add an indication for the reduction of the risk of vascular mortality in patients with a suspected acute myocardial infarction in aspirin professional labeling ("The Tan Sheet" June 17, p. 3). The group also urges FDA to add the treatment of acute MI to the professional labeling section of the monograph for aspirin...